Galux Unveils Breakthrough AI Technology for Therapeutic Antibody Loop Design

• Next-generation AI platform “GaluxDesign” expected to accelerate antibody drug development and establish new standards in biologics innovation

Galux has announced the release of its proprietary therapeutic antibody loop design AI technology, GaluxDesign, through the global life sciences preprint platform bioRxiv. This breakthrough technology is expected to significantly advance the development of antibody-based drugs across oncology, autoimmune disorders, and infectious diseases.

Unlike general protein design, designing therapeutic antibodies is inherently more complex due to their origin in adaptive immunity and lack of evolutionary information from the metagenome. Additionally, antibodies recognize their targets primarily through flexible loop regions, making it difficult for conventional AI models—such as AlphaFold by Google DeepMind, which focus on globular protein structure prediction—to accurately model antibody-antigen complexes.

GaluxDesign directly addresses these challenges by offering high-resolution, atomic-level precision in modeling antibody loop structures, which are critical for binding to disease-related proteins and foreign antigens. The company’s newly published paper demonstrates the application of this technology to four distinct drug targets, highlighting its versatility and performance. According to Galux, GaluxDesign outperforms the antibody design technology published by U.S.-listed company Absci by a factor of five in design accuracy.

Building on this technological breakthrough, Galux plans to accelerate the development of its internal drug discovery pipeline and expand collaborative research with global pharmaceutical and biotech companies to bring novel therapeutics to market.

“In a rapidly evolving field where the impact of AI on drug discovery is becoming increasingly evident, GaluxDesign represents a major step forward in the rational design of therapeutic antibodies,” the company said. “We have already signed a collaboration agreement with LG Chem to apply this technology to the development of next-generation cancer therapeutics.”